תזונה ותוספים standard dietary treatment versus a low-carbohydrate/high-protein diet or the Lighter

[Mike Bikov]

J Diabetes. 2009 Sep;1(3):207-17. doi: 10.1111/j.1753-0407.2009.00033.x. Epub 2009 Jun 26.
Randomized clinical trial of standard dietary treatment versus a low-carbohydrate/high-protein diet or the LighterLife Programme in the management of obesity*.

Rolland C, Hession M, Murray S, Wise A, Broom I.

Centre for Obesity Research and Epidemiology School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen LighterLife, Cavendish House, Harlow Business Park, Parkway, Harlow, Essex, UK.
Abstract

Background:   With the current obesity epidemic, the search for effective weight loss approaches is required. In the present study, changes in weight, body composition and cardiovascular (CV) risk in response to a low-fat, reduced-energy diet (LFRE), a low-carbohydrate/high-protein diet (LCHP), or a commercially available very low-calorie diet (LighterLife; LL) were assessed. Methods:  One hundred and twenty obese patients (body mass index ≥35 kg/m(2) ) underwent a screening period of 3 months on the LFRE. Those who lost >5% of their body weight were maintained on this approach for an additional 3 months, whereas those who lost >10% at this time were maintained for 1 year. Patients failing to achieve these targets were randomly allocated to either the LCHP (n = 38) or LL (n = 34) for a period of 9 months. Results:  Significantly greater weight loss was seen for patients on the LL than the LCHP at 3 (mean (±SD) -11.6 ± 12.9 vs -2.8 ± 4.5 kg, respectively; P < 0.0001) and 9 months (-15.1 ± 21.1 vs -1.9 ± 5.0 kg, respectively; P < 0.0001) after screening. Significantly greater improvement in total cholesterol, low-density lipoprotein-cholesterol, fasting glucose, and diastolic blood pressure was seen at 3 months in patients on the LL compared with the LCHP (P < 0.05). These differences were no longer significant at 9 months, with the exception of fasting glucose. The attrition rate was elevated in the LCHP group, but did not differ significantly from the LL group. Conclusion:  Greater weight loss and improved CV risk were achieved with the LL, which mostly reflects the patient support provided for each dietary treatment.

PMID: 20923540 [PubMed - in process]

✌️✌️
​

 

[אבי כהן]

כמובן שצריך לקרוא את המלא אבל מאיך שהדברים מוצגים פה משתמע שהחבר'ה שעל דיאטת ה LL פשוט
הכניסו הרבה פחות קלוריות...אם זה כך, לא מי יודע מה מפתיע שהם ירדו במשקל.

מענין כמובן מה משמעות LighterLife Programme (גם בלי גוגל סיכוי טוב שמדובר בגורם מסחרי)